Samsung Bioepis Moves Swiftly To Denosumab Phase III

SB16 Biosimilar Rival To Prolia Progresses To Phase III Trials

 
• By Dave Wallace

Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.

Clinical Trial
Samsung Bioepis’ SB16 Denosumab Biosimilar Moves To Phase III • Source: Shutterstock

More from Biosimilars

More from Products